Soluble guanylate cyclase activators for treatment of portal hypertension

By using a combination of soluble guanylate cyclase activator and SGLT2 inhibitor, the problem of difficulty in reducing portal hypertension and improving liver perfusion in the prior art is solved, and compensatory cirrhosis and clinically significant portal hypertension is achieved. Effective treatment reduces the risk of complications and improves the quality of life of patients.

CN118900690AInactive Publication Date: 2024-11-05BOEHRINGER INGELHEIM INT GMBH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202380028647.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-21
Filing Date
2023-03-20
Publication Date
2024-11-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively reduce portal hypertension and improve liver perfusion, especially in patients with poor tolerance to nonselective beta-blockers or carvedilol. There is an unmet medical need.

Method used

Use a combination of soluble guanylate cyclase activator (sGC activator) with sodium-glucose cotransporter-2 (SGLT2) inhibitors to treat compensatory cirrhosis and clinically significant portal hypertension, reducing portal hypertension Pressure and improved liver perfusion.

Benefits of technology

This combination therapy significantly reduces portal hypertension, improves liver perfusion, reduces the risks of ascites, varicose hemorrhage and hepatic encephalopathy, and improves the patient's quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118900690A_ABST
    Figure CN118900690A_ABST
Patent Text Reader

Abstract

The present invention relates to a method for treating a patient suffering from compensatory cirrhosis comprising administering to a patient in need thereof a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the use of certain soluble guanylate cyclase activators for the treatment of certain conditions, including portal hypertension. The present invention further relates to the use of a soluble guanylate cyclase activator in combination with a sodium-glucose co-transporter-2 (SGLT2) inhibitor. [Background technology]

[0002] Cirrhosis is an end-stage liver condition caused by a variety of chronic diseases, such as hepatitis C virus infection (HCV), chronic alcohol abuse, or metabolic syndrome with nonalcoholic fatty liver disease (NAFLD). Cirrhosis itself is a chronic condition with a high mortality rate. It is a heterogeneous disease that is classified into two main prognostic stages: compensated and decompensated cirrhosis. This classification depends on the presence or absence of clinically apparent decompensation events (specifically ascites [not just perihepatic ascites]), variceal bleeding (VH), and / or mimic hepatic encephalopathy (HE). (See, e.g., G. Garcia-Tsao et al., "Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management": 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2017; 65(1): 310–335.) Currently, there are no treatments available for cirrhosis to reduce fibrotic tissue or regenerate hepatocytes. The main goals of treatment are to delay decompensation, improve quality of life, and treat symptoms of cirrhosis, especially decompensation.

[0003] Portal hypertension (PH) is the initial and major consequence of cirrhosis and is responsible for most of its complications. (See, e.g., GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385(9963): 117–171). The only currently recommended clinical approach to prevent PH-related decompensation events in patients with compensated cirrhosis is endoscopic variceal ligation or off-label use of non-selective beta-blockers (NSBBs) or carvedilol to prevent the first variceal bleeding.

[0004] However, not all patients with PH achieve a hemodynamic response to these current treatment options. NSBBs and carvedilol are currently used to prevent complications of cirrhosis and improve patient survival, but these benefits occur in less than half of the patients treated, and most occur in those patients who achieve a significant reduction in portal pressure. There remains an unmet need for a large number of patients who cannot tolerate treatment with NSBBs or carvedilol due to lowering of systemic blood pressure (BP) and heart rate (HR), and who are at higher risk of further progression to decompensation.

[0005] Therefore, there is an unmet medical need to reduce portal pressure and improve liver perfusion in this patient population with PH, especially clinically significant portal hypertension (CSPH) and compensated cirrhosis. CSPH is associated with an increased risk of developing ascites, overt clinical decompensation (ascites, VH and HE), postoperative decompensation and hepatocellular carcinoma. (See, e.g., C. Villanueva et al., "Development of hyperdynamic circulation and response to betablockers incompensated cirrhosis with portal hypertension". Hepatology, 2016;63(1):197-206; G. D'Amico et al., "Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494patients". Aliment Pharmacol Ther 2014;39(10):1180-1193; and G. Garcia-Tsao et al., "Portal hypertensive bleeding incirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases". Hepatology 2017;65(1):310–335). [Summary of the invention]

[0006] The present invention relates to a method for treating a patient with compensated liver cirrhosis, comprising administering to the patient a pharmaceutically effective amount of a soluble guanylate cyclase (sGC) activator or a pharmaceutically acceptable salt thereof.

[0007] The present invention also relates to a sGC activator or a pharmaceutically acceptable salt thereof for use in treating a patient with compensated liver cirrhosis.

[0008] In another embodiment, the present invention is directed to a method for treating a patient with clinically significant portal hypertension in compensated cirrhosis comprising administering to the patient a therapeutically effective amount of a sGC activator or a pharmaceutically acceptable salt thereof.

[0009] In another embodiment, the present invention relates to a sGC activator or a pharmaceutically acceptable salt thereof for use in treating a patient with clinically significant portal hypertension in compensated cirrhosis.

[0010] In another embodiment, the present invention is directed to a method for reducing portal pressure in a patient with clinically significant portal hypertension in compensated cirrhosis comprising administering to the patient a therapeutically effective amount of a sGC activator or a pharmaceutically acceptable salt thereof.

[0011] In one embodiment, CSPH in compensated cirrhosis is due to or caused by hepatitis B virus (HBV), hepatitis C virus (HCV), or non-alcoholic steatohepatitis (NASH).

[0012] In another embodiment, the present invention is directed to a method for treating a patient with clinically significant portal hypertension in compensated cirrhosis, comprising administering to the patient a therapeutically effective amount of a sGC activator or a pharmaceutically acceptable salt thereof, wherein the CSPH in compensated cirrhosis is due to or caused by HBV, HCV or NASH.

[0013] In one embodiment, the invention relates to a method for treating a patient suffering from clinically significant portal hypertension in compensated cirrhosis due to HBV.

[0014] In another embodiment, the invention is directed to a method for treating a patient suffering from clinically significant portal hypertension in compensated cirrhosis due to HCV.

[0015] In another embodiment, the invention relates to a method for treating a patient suffering from clinically significant portal hypertension in compensated cirrhosis due to NASH.

[0016] In another embodiment, the invention is directed to a method for treating a patient with clinically significant portal hypertension in compensated cirrhosis due to NASH, wherein the patient has type 2 diabetes.

[0017] In another embodiment, the invention relates to a method for treating a patient with clinically significant portal hypertension in compensated cirrhosis due to NASH, wherein the patient does not have type 2 diabetes.

[0018] In another embodiment, the present invention relates to any one of the methods or uses described above, further comprising administering a pharmaceutically effective amount of a SGLT2 inhibitor or a pharmaceutically acceptable salt thereof.

[0019] In another embodiment, the present invention relates to a method for treating a patient with compensated cirrhosis due to NASH, the method comprising administering to the patient a pharmaceutically effective amount of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically effective amount of a SGLT2 inhibitor or a pharmaceutically acceptable salt thereof.

[0020] In another embodiment, the present invention relates to a method for treating a type 2 diabetic patient suffering from CSPH in compensated cirrhosis due to NASH, the method comprising administering to the patient a pharmaceutically effective amount of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically effective amount of a SGLT2 inhibitor or a pharmaceutically acceptable salt thereof.

[0021] In another embodiment, the SGLT2 inhibitor, when used, is selected from the group consisting of empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin, licogliflozin and ipragliflozin.

[0022] In another embodiment, the invention relates to the immediately above embodiment, wherein the SGLT2 inhibitor is selected from the group consisting of empagliflozin, dapagliflozin and canagliflozin.

[0023] In another embodiment, the invention relates to the immediately above mentioned embodiment, wherein the SGLT2 inhibitor is empagliflozin.

[0024] In another embodiment, the present invention relates to a method for treating a patient suffering from CSPH in compensated cirrhosis due to NASH, the method comprising administering to the patient a pharmaceutically effective amount of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically effective amount of empagliflozin.

[0025] In another embodiment, the present invention relates to a method for treating a type 2 diabetic patient suffering from CSPH in compensated cirrhosis due to NASH, the method comprising administering to the patient a pharmaceutically effective amount of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically effective amount of empagliflozin.

[0026] Within the scope of the present invention, the SGLT2 inhibitor may also inhibit SGLT1, ie a dual SGLT1 / SGLT2 inhibitor. In one embodiment, when used, the SGLT2 inhibitor is a dual SGLT1 / SGLT2 inhibitor selected from the group consisting of sogliflozin and linagliptin.

[0027] WO 2014 / 039434 and WO 2020 / 011804 describe oral sGC small molecule activators ("sGC activators of the present invention") that can be used in the methods of the present invention. Unless otherwise indicated herein, the terms "sGC activators of the present invention", "compounds of the present invention" and "compounds of formula (I)" are used interchangeably.

[0028] In one embodiment of the present invention, the sGC activator used in the method of the present invention is a compound of formula (I)

[0029]

[0030] in:

[0031] A is a 5- to 7-membered saturated heterocyclic group containing one nitrogen and optionally one oxygen, wherein one carbon of the heterocyclic group is optionally substituted by one or two selected from C 1-3 Alkyl and oxo group substitution;

[0032] R 1 is C optionally substituted by methoxy 1-4 alkyl;

[0033] R 2 Selected from H, F, Cl, C 1-3 Alkyl, -CN, -OMe and -CF3;

[0034] R 3 Selected from H and –CH3;

[0035] R 4 is selected from H, F, -CH3 and -OMe;

[0036] R 5 is selected from H, Cl, -CH3, -CH2CH3, -CF3, F and -OMe;

[0037] R 6 bonded to the nitrogen on A and selected from H, C 1-6 Alkyl, -(CH2) n C 3-6 Cycloalkyl, -C(O)C 1-6 Alkyl, -(CH2) n Heterocyclic group, -(CH2) n Aryl, -(CH2) n Heteroaryl, -SO2aryl, SO2C 1-6 Alkyl, wherein the C 1-6 Alkyl, -(CH2) n Heterocyclic group, -(CH2) n Cycloalkyl, -(CH2) nAryl and -(CH2) n Heteroaryl is optionally substituted by one to four independently selected 1-3 Alkyl, halogen, C 1-3 Alkoxy, -CF3, -OH, oxo, -(CH2) 1-3 O(CH2) 2-3 OH and -SO2CH3 group substitution;

[0038] R 7 is selected from H, -CH3, -CH2CH3, -CF3, F and -CN;

[0039] n is 0, 1 or 2;

[0040] or a salt thereof.

[0041] In another embodiment, the invention relates to the method described in the above embodiments, wherein:

[0042] A is a 5- to 7-membered saturated heterocyclic group containing one nitrogen atom, wherein one carbon atom of the heterocyclic group is optionally substituted by one or two C 1-3 Alkyl substitution;

[0043] R 1 C 1-3 alkyl;

[0044] R 2 Selected from H, F, Cl, C 1-3 Alkyl, -CN, -OMe and -CF3;

[0045] R 3 Selected from H and -CH3;

[0046] R 4 Selected from H and F;

[0047] R 5 is selected from H, Cl and -CH3;

[0048] R 6 bonded to the nitrogen on A and selected from H, C 1-6 Alkyl, -(CH2) n C 3-6 Cycloalkyl, -C(O)C 1-6 Alkyl, -(CH2) n Heterocyclic group, -(CH2) n Aryl and -(CH2) n Heteroaryl, wherein the C 1-6 Alkyl, -(CH2) n Heterocyclic group, -(CH2) n Cycloalkyl, -(CH2) n Aryl and -(CH2) nHeteroaryl is optionally substituted by one to four independently selected 1-3 Alkyl, halogen, C 1-3 Alkoxy, -CF3, -OH and -SO2CH3 group substitution;

[0049] R 7 is H; and

[0050] n is 0, 1 or 2;

[0051] or a salt thereof.

[0052] In another embodiment, the present invention relates to a method as described in any one of the above embodiments, wherein:

[0053] R 1 is methyl, ethyl or isopropyl; and

[0054] Group Selected from:

[0055]

[0056] or a salt thereof.

[0057] In another embodiment, the present invention relates to a method as described in any one of the above embodiments, wherein:

[0058] R 2 is selected from -CH3, F, Cl and -CF3; and

[0059] R 6 Selected from H, C 1-6 Alkyl, -(CH2) n C 3-6 Cycloalkyl, -C(O)C 1-6 Alkyl and -(CH2) n Heterocyclic group, wherein the C 1-6 Alkyl, -(CH2) n Cycloalkyl and -(CH2) n The heterocyclic group is optionally substituted by one to four independently selected 1-3 Alkyl, halogen, C 1-3 Alkoxy, -CF3, -OH and -SO2CH3 group substitution;

[0060] or a salt thereof.

[0061] In another embodiment, the present invention relates to a method as described in any one of the above embodiments, wherein in R 6The heterocyclic group mentioned in the above is selected from oxetane, tetrahydrofuran, tetrahydropyran, 2-oxabicyclo[3.2.0]heptyl, 1,4-dioxanyl, 8-oxabicyclo[3.2.1]octanyl, 1-oxaspiro[4.5]decanyl and pyrrolidin-2-one;

[0062] In R 6 The heteroaryl mentioned in is selected from imidazolyl, isoxazolyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, thiazolyl and 4,5,6,7-tetrahydrobenzothiazolyl; and

[0063] In R 6 The aryl group mentioned in is phenyl;

[0064] or a salt thereof.

[0065] In another embodiment, the present invention relates to a method as described in any one of the above embodiments, wherein:

[0066] R 6 -(CH2) n Heterocyclyl, wherein the heterocyclyl is selected from oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 2-oxabicyclo[3.2.0]heptyl, 1,4-dioxanyl, 8-oxabicyclo[3.2.1]octanyl and 1-oxaspiro[4.5]decanyl;

[0067] or a salt thereof.

[0068] In another embodiment, the present invention relates to a method as described in any one of the above embodiments, wherein:

[0069] R 2 is -CH3;

[0070] R 3 is H;

[0071] R 4 is H or -CH3;

[0072] R 5 is H or -CH3;

[0073] R 7 In R 5 The para position is H, -CH3 or -CH2CH3;

[0074] or a salt thereof.

[0075] In another embodiment, the present invention relates to a method as described in any one of the above embodiments, wherein:

[0076] Group for

[0077] or a salt thereof.

[0078] In another embodiment, the present invention relates to a method as described in any one of the above embodiments, wherein:

[0079] R 3 is H; and

[0080] R 4 is H;

[0081] or a salt thereof.

[0082] Table 1 shows representative compounds of the invention that can be used according to the methods of the invention.

[0083] Table 1

[0084]

[0085]

[0086]

[0087]

[0088]

[0089]

[0090]

[0091]

[0092]

[0093]

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[0100]

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113] In one embodiment, the sCG activator used in the method of the present invention is selected from any one of the compounds described in Table 1 above and a pharmaceutically acceptable salt thereof.

[0114] In another embodiment, the sCG activator used in the method of the present invention is selected from the group consisting of Compound Nos. 1, 2, 3, 4, 5, 7, 8, 9, 12, 15, 16, 18, 21, 27, 28, 30, 31, 35, 36, 39, 41, 42, 44, 45, 46, 47, 48, 57, 59, 62, 68, 77, 78, 79, 80, 82, 83, 84, 85, 86, 88, 92, 93 and 94 and pharmaceutically acceptable salts thereof (such compounds as described in Table 1).

[0115] In another embodiment, the sCG activator used in the method of the present invention is selected from the group consisting of compound numbers 95, 97, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126 , 127, 128, 129, 130, 131, 132, 136, 137, 139, 140, 141, 142, 145, 146, 152, 153, 154, 155, 157, 158, 159, 161, 162, 163, 164, 165, 166, 167, 169, 170, 171, 172, 173, 174, 175, 176, 177 , 178, 179, 180, 181, 184, 185, 186, 187, 188, 189, 191, 193, 194, 195, 196, 197, 198, 199, 201, 202, 203, 204, 205, 206, 207, 208, 210, 211, 212, 213, 214, 215, 216, 220, 222, 223, 224 , 225, 227, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257 and pharmaceutically acceptable salts thereof (such compounds as described in Table 1).

[0116] In one embodiment, when used in the methods of the present invention, the SGLT2 inhibitor is selected from the group consisting of empagliflozin, dapagliflozin and canagliflozin.

[0117] In another embodiment, when used in the methods of the present invention, the SGLT2 inhibitor is empagliflozin.

Brief Description of the Drawings

[0118] Figure 1 Schematic diagram showing the experimental design of a four-arm clinical trial investigating the effect of an oral sGC activator of the invention alone and in combination with empagliflozin on portal hypertension after 8 weeks of treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis. Figure 1As shown in the figure, the four teams or treatment groups are as follows: HBV team (BID treatment of sGC activator alone); HCV team (BID treatment of sGC activator alone), NASH team without type 2 diabetes (BID treatment of sGC activator alone); and NASH team with type 2 diabetes (BID treatment of sGC activator alone and QD treatment of empagliflozin). [Specific implementation method]

[0119] abbreviation:

[0120]

[0121]

[0122] As used herein, the term "compensated cirrhosis" refers to the absence of clinically apparent decompensatory events such as, for example, ascites [not just perihepatic ascites], variceal bleeding (VH), and / or mimic hepatic encephalopathy (HE).

[0123] As used herein, the term "clinically significant portal hypertension" (CSPH) refers to a hepatic venous pressure gradient (HVPG) greater than or equal to 10 mm Hg. In addition to such quantitative measurements of CSPH, the term "CSPH" may also refer to clinical signs of CSPH, such as esophagogastric varices, splenomegaly, thrombocytopenia, porto-systemic shunt, and other clinical signs of CSPH. Methods for measuring HVPG, esophagogastric varices, splenomegaly, thrombocytopenia, porto-systemic shunt, and other clinical signs of CSPH are known in the art and / or described herein.

[0124] Unless specifically indicated otherwise, throughout the specification and the appended claims, a given chemical formula or name shall include tautomers and all stereo, optical and geometric isomers thereof (e.g., enantiomers, diastereomers, E / Z isomers, etc.) and racemates thereof, as well as mixtures of isolated enantiomers in varying proportions, mixtures of diastereomers, or mixtures of any of the foregoing forms in which such isomers and enantiomers exist, and salts thereof, including pharmaceutically acceptable salts thereof and solvates thereof, such as, for example, hydrates, including solvates of free compounds or solvates of salts of compounds.

[0125] Some compounds of formula (I) may exist in more than one tautomeric form. The present invention includes methods of using all such tautomers.

[0126] The present invention includes pharmaceutically acceptable derivatives of compounds of formula (I). "Pharmaceutically acceptable derivatives" refers to any pharmaceutically acceptable salt or ester, or any other compound, which, when administered to a patient, is capable of (directly or indirectly) providing a compound useful in the present invention or a pharmacologically active metabolite or pharmacologically active residue thereof. Pharmacologically active metabolites are understood to mean any compound of the present invention that can be metabolized enzymatically or chemically. This includes, for example, hydroxylated or oxidized derivative compounds of formula (I).

[0127] As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by preparing acid addition salts or base addition salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. For example, such salts include acetates, ascorbates, benzenesulfonates, benzoates, bicarbonates, bitartrates, bromides / hydrobromides, edetates, camsylates, carbonates, chlorides / hydrochlorides, citrates, edisylates, estolates, ethanesulfonates, fumarates, glucoheptonates, gluconates, glutamates, glycolates, glycollylarsnilates, hexylresorcinates, hydrabamines, hydroxymaleates, hydroxynaphthoates, iodides, isothiona ... te), lactate, lactobionate, malate, maleate, mandelate, methanesulfonate, methyl bromide, methyl nitrate, methyl sulfate, mucate, naphthenate, nitrate, oxalate, pamoate, pantothenate, phenylacetate, phosphate / diphosphate, polygalacturonate, propionate, salicylate, stearate, subacetate, succinate, sulfonamide, sulfate, tannate, tartrate, theochlorate, toluenesulfonate, triethyl iodide, ammonium, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine and procaine. Other pharmaceutically acceptable salts can be formed with cations from metals such as aluminum, calcium, lithium, magnesium, potassium, sodium, zinc, etc. (see also Pharmaceutical salts, Birge, SM et al., J. Pharm. Sci., (1977), 66, 1-19).

[0128] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods. Generally speaking, such salts can be prepared by reacting the free acid or base form of such compounds with a sufficient amount of a suitable base or acid in water or in an organic diluent (such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile, or a mixture thereof).

[0129] Salts of acids other than those mentioned above, which are useful, for example, for purifying or isolating the compounds of the invention (eg trifluoroacetate salts), also form part of the present invention.

[0130] In addition, prodrugs of compounds of formula (I) are used within the scope of the present invention. Prodrugs include those compounds that are modified after simple chemical transformation to produce the compounds of the present invention. Simple chemical transformations include hydrolysis, oxidation and reduction. Specifically, when the prodrug is administered to a patient, the prodrug can be converted to the compounds disclosed above, thereby imparting the desired pharmacological effect.

[0131] As will be appreciated by those skilled in the art, the compounds of the present invention are only those that are considered to be "chemically stable." For example, compounds with "dangling valencies" or "carbanions" are not contemplated compounds for the inventive methods disclosed herein.

[0132] For all compounds disclosed herein above, if the nomenclature conflicts with the structure, it is understood that the compound is defined by the structure.

[0133] Unless otherwise specified, all terms used in this specification should be understood in their ordinary meanings as known in the art. For example, “C 1-4 "Alkyl" is a saturated aliphatic hydrocarbon monovalent group containing 1 to 4 carbons, such as methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl or tert-butyl; "C 1-4 "Alkoxy" is a C 1-4 Alkyl, such as methoxy, ethoxy, propoxy, butoxy. Where structurally possible and unless otherwise specified, all alkyl, alkenyl and alkynyl groups are understood to be branched or unbranched, cyclic or acyclic. Other more specific definitions are as follows:

[0134] The term "C 1-n "alkyl" (wherein n is an integer from 2 to n), alone or in combination with another group, means a non-cyclic, saturated, branched or straight-chain hydrocarbon group having 1 to n C atoms. For example, the term C 1-5Alkyl groups include the groups H3C-, H3C-CH2-, H3C-CH2-CH2-, H3C-CH(CH3)-, H3C-CH2-CH2-CH2-, H3C-CH2-CH(CH3)-, H3C-CH(CH3)-CH2-, H3C-C(CH3)2-, H3C-CH2-CH2-CH2-CH2-, H3C-CH2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH(CH3)-CH2-, H3C-CH2-CH2-CH(CH3)-, H3C-CH2-CH(CH3)-CH2-, H3C-CH(CH3)-CH2-, H3C-CH2-C(CH3)2-, H3C-C(CH3)2-CH2-, H3C-CH(CH3)-CH(CH3)- and H3C-CH2-CH(CH2CH3)-.

[0135] The term "C 1-n "alkylene" (wherein n is an integer from 1 to n), alone or in combination with another group, means a non-cyclic, straight-chain or branched divalent alkyl group containing from 1 to n carbon atoms. For example, the term C 1-4 Alkenyl groups include -(CH2)-, -(CH2-CH2)-, -(CH(CH3))-, -(CH2-CH2-CH2)-, -(C(CH3)2)-, -(CH(CH2CH3))-, -(C H(CH3)-CH2)-, -(CH2-CH(CH3))-, -(CH2-CH2-CH2-CH2)-, -(CH2-CH2-CH(CH3))-, -(CH(CH3)-CH2- CH2)-, -(CH2-CH(CH3)-CH2)-, -(CH2-C(CH3)2)-, -(C(CH3)2-CH2)-, -(CH(CH3)-CH(CH3))-, -(CH2 -CH(CH2CH3))-, -(CH(CH2CH3)-CH2)-, -(CH(CH2CH2CH3))-, -(CHCH(CH3)2)-, and –C(CH3)(CH2CH3)-.

[0136] The term "C 3-n "Cycloalkyl" (wherein n is an integer from 4 to n), alone or in combination with another group, means a cyclic, saturated, unbranched hydrocarbon radical having 3 to n C atoms. For example, the term C 3-7 Cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.

[0137] The term "heteroatom" as used herein shall be understood to mean atoms other than carbon, such as O, N, S and P.

[0138] In all alkyl groups or carbon chains, one or more carbon atoms may be optionally replaced by heteroatoms: O, S or N, it being understood that if N is unsubstituted, it is NH, it being also understood that such heteroatoms may replace terminal carbon atoms or internal carbon atoms within a branched or unbranched carbon chain. Such groups may be substituted as described above with groups such as oxo to obtain definitions such as, but not limited to, alkoxycarbonyl, acyl, amido and thiono.

[0139] The term "aryl" as used herein, alone or in combination with another group, refers to a carbocyclic aromatic monocyclic group containing 6 carbon atoms, which may be further fused to another 5- or 6-membered carbocyclic group, which may be aromatic, saturated or unsaturated. Aryl includes, but is not limited to, phenyl, dihydroindenyl, indenyl, naphthyl, anthracenyl, phenanthrenyl, tetrahydronaphthyl and dihydronaphthyl.

[0140] The term "heteroaryl" means an aromatic 5- to 6-membered monocyclic heteroaryl or an aromatic 7- to 11-membered heteroaryl bicyclic ring, wherein at least one of the rings is aromatic, wherein the heteroaryl ring contains 1 to 4 heteroatoms such as N, O and S. Non-limiting examples of 5- to 6-membered monocyclic heteroaryl rings include furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, pyrrolyl, imidazolyl, tetrazolyl, triazolyl, thienyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl and purinyl. Non-limiting examples of 7- to 11-membered heteroaryl bicyclic heteroaryl rings include benzimidazolyl, quinolinyl, dihydro-2H-quinolinyl, isoquinolinyl, quinazolinyl, indazolyl, thieno[2,3-d]pyrimidinyl, indolyl, isoindolyl, benzofuranyl, benzopyranyl, benzodioxolyl, benzoxazolyl, and benzothiazolyl.

[0141] The term "heterocyclyl" means a stable non-aromatic 4 to 8-membered monocyclic heterocyclic group or a stable non-aromatic 6 to 11-membered fused bicyclic, bridged bicyclic or spirocyclic heterocyclic group. The 5 to 11-membered heterocyclic ring is composed of carbon atoms and one or more (preferably one to four) heteroatoms selected from nitrogen, oxygen and sulfur. The heterocyclic ring may be saturated or partially unsaturated. Non-limiting examples of non-aromatic 4 to 8-membered monocyclic heterocyclic groups include tetrahydrofuranyl, azetidinyl, pyrrolidinyl, pyranyl, tetrahydropyranyl, dioxanyl, thiomorpholinyl, 1,1-dioxo-1λ 6 -thiomorpholinyl, morpholinyl, piperidinyl, piperazinyl and nitrogen Non-limiting examples of non-aromatic 6 to 11-membered fused bicyclic groups include octahydroindolyl, octahydrobenzofuranyl, and octahydrobenzothienyl. Non-limiting examples of non-aromatic 6 to 11-membered bridged bicyclic groups include 2-azabicyclo[2.2.1]heptyl, 3-azabicyclo[3.1.0]hexyl, and 3-azabicyclo[3.2.1]octanyl. Non-limiting examples of non-aromatic 6 to 11-membered spirocyclic heterocyclic groups include 7-aza-spiro[3,3]heptyl, 7-spiro[3,4]octanyl, and 7-aza-spiro[3,4]octanyl. The term "heterocyclyl" is intended to include all possible isomeric forms.

[0142] The term "halogen" as used in this specification is understood to mean bromine, chlorine, fluorine or iodine. Definitions "halogenated", "partially or fully halogenated", "partially or fully fluorinated", "substituted with one or more halogen atoms" include, for example, mono-, di- or tri-halogenated derivatives based on one or more carbon atoms. For alkyl, non-limiting examples are -CH2CHF2, -CF3, etc.

[0143] Each alkyl, cycloalkyl, heterocycle, aryl or heteroaryl group, or the like described herein is understood to be optionally partially or fully halogenated.

[0144] As used herein, "nitrogen" or N and "sulfur" or S include any oxidized forms of nitrogen and sulfur and any quaternized forms of basic nitrogen. For example, for -SC 1-6 Unless otherwise specified, alkyl groups are understood to include -S(O)-C 1-6 Alkyl and -S(O)2-C 1-6 Alkyl, similarly, when R a When it is phenyl, -SR a It can be represented as phenyl-S(O) m - and wherein m is 0, 1 or 2.

[0145]

General synthesis method

[0146] The compounds of formula (I) used in the method of the present invention can be prepared by the methods and examples described in WO 2014 / 039434.

[0147]

Methods of therapeutic use

[0148] For therapeutic use, when used, each of the compounds of formula (I) and the SGLT2 inhibitors can be administered in any conventional manner via a pharmaceutical composition of any conventional pharmaceutical dosage form. Conventional dosage forms typically include a pharmaceutically acceptable carrier suitable for the selected specific dosage form. Administration routes include, but are not limited to, intravenous, intramuscular, subcutaneous, intrasynovial, by infusion, sublingual, transdermal, oral, topical or by inhalation. Preferred modes of administration are oral and intravenous.

[0149] When used, the compound of formula (I) and the SGLT2 inhibitor can be administered alone or in combination with an adjuvant, which enhances the stability of the inhibitor, promotes the administration of the pharmaceutical composition containing it in certain embodiments, provides increased dissolution or dispersion, increases inhibitory activity, provides adjuvant therapy, etc., including other active ingredients. In one embodiment, for example, a variety of compounds of the present invention can be administered. Advantageously, such combination therapy utilizes lower doses of conventional therapeutic agents, thus avoiding possible toxicity and adverse side effects that occur when those agents are used as monotherapy. The compounds of the present invention can be physically combined with conventional therapeutic agents or other adjuvants into a single pharmaceutical composition. Advantageously, the compounds can then be administered together in a single dosage form. In some embodiments, the pharmaceutical compositions of such combinations containing compounds contain at least about 5%, but more preferably at least about 20% of the compound of formula (I) (w / w) or a combination thereof. The most preferred percentage (w / w) of the compounds of the present invention can be changed and is within the scope of those skilled in the art. Alternatively, the compounds of the present invention and conventional therapeutic agents or other adjuvants can be administered separately (continuously or in parallel). Separate administration allows for greater flexibility in the dosing regimen.

[0150] In one embodiment, the present invention relates to a method for treating compensated liver cirrhosis, comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutically effective amount of the sGC activator of the present invention or a pharmaceutically acceptable salt thereof.

[0151] In another embodiment, the present invention relates to a pharmaceutical composition comprising a sGC activator of the present invention for use in treating a patient suffering from compensated cirrhosis.

[0152] As described above, when used, the dosage form of the compound of formula (I) of the present invention and the SGLT2 inhibitor may include pharmaceutically acceptable carriers and adjuvants known to those of ordinary skill in the art and suitable for dosage forms. Such carriers and adjuvants include, for example, ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes, and cellulose-based substances. Preferred dosage forms include tablets, capsules, caplets, liquids, solutions, suspensions, emulsions, lozenges, syrups, resolvable powders, granules, suppositories, and transdermal patches. The method for preparing such dosage forms is known (see, for example, HC Ansel and NG Popovish, Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th edition, Lea and Febiger (1990)). Specific dosage and treatment regimen will depend on factors such as the patient's general health profile, the severity and course of the patient's illness or the treatment thereof, and the judgment of the attending physician.

[0153] Within the present invention it is understood that the combination or combined use of a sGC activator and a SGLT2 inhibitor according to the present invention may envisage simultaneous, sequential or separate administration of the therapeutic components.

[0154] In the present context, "combination" or "combined" within the meaning of the present invention may include, but is not limited to, fixed and non-fixed (e.g., free) forms (including kits, or other administration, application or dosage forms) and uses, such as, for example, simultaneous, continuous or separate use of sGC activators and SGLT2 inhibitors. In the present context, "combination" or "combined" within the meaning of the present invention may further include additional therapeutic agents or concomitant therapies as described herein.

[0155] The combined administration or use of the present invention can be carried out by administering the therapeutic components together, such as, for example, by administering them simultaneously in a single formulation or in two separate formulations. Alternatively, the administration can be carried out by administering the therapeutic components continuously, such as, for example, sequentially in two separate formulations.

[0156] For the combination therapies of the present invention, the therapeutic components may be administered separately (which means they are formulated separately) or formulated together (which means they are formulated into the same preparation). Thus, the administration of one element of the combination of the present invention may be before, at the same time, or after the administration of another element of the combination.

[0157] In one embodiment, the methods of the invention comprise administering to the patient a daily dose of 0.1 mg to about 50 mg of a sGC activator of the invention, or a pharmaceutically acceptable salt thereof.

[0158] In another embodiment, the methods of the invention comprise administering to the patient a daily dose of 1 mg to about 30 mg of a sGC activator of the invention or a pharmaceutically acceptable salt thereof.

[0159] In another embodiment, the sGC activator of the present invention or a pharmaceutically acceptable salt thereof is administered to the patient at a daily dose of 0.1 to 100 mg; or 1 to 25 mg; or 1 to 10 mg; or 2 to 5 mg.

[0160] In another embodiment, the sGC activator of the present invention or a pharmaceutically acceptable salt thereof is administered to the patient in an amount selected from the group consisting of 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg and 10 mg.

[0161] In another embodiment, the sGC activator of the present invention or a pharmaceutically acceptable salt thereof is administered to the patient in an amount selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 mg.

[0162] In another embodiment, the methods of the invention comprise administering to the patient up to 3 mg of a sGC activator of the invention, or a pharmaceutically acceptable salt thereof.

[0163] In another embodiment, the method of the present invention comprises administering to the patient 1 mg of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof.

[0164] In another embodiment, the method of the present invention comprises administering to the patient 2 mg of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof.

[0165] In another embodiment, the method of the present invention comprises administering to the patient 3 mg of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof.

[0166] The vasodilation of the sGC activator may lead to orthostatic dysregulation and hypotensive episodes. Titration of the sGC activator may allow the total daily exposure of the sGC activator to be further increased while avoiding high peak concentrations.

[0167] In one embodiment, the present invention relates to a method for preventing or reducing the severity of orthostatic dysregulation caused by, resulting from, or associated with the administration of a sGC activator or a pharmaceutically acceptable salt thereof, the method comprising administering a daily dose of a sGC activator to the patient BID, TID, or QID.

[0168] In another embodiment, the invention relates to the method immediately above, wherein the sGC activator is administered BID.

[0169] In another embodiment, the methods of the present invention comprise administering to a patient up to 3 mg of a sGC activator of the present invention, or a pharmaceutically acceptable salt thereof, twice daily.

[0170] In another embodiment, the methods of the present invention comprise administering 3 mg of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof to a patient twice daily to provide a total daily amount of 6 mg of sGC activator.

[0171] In another embodiment, the methods of the present invention comprise administering 2 mg of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof to a patient twice daily to provide a total daily amount of 4 mg of sGC activator.

[0172] In another embodiment, the methods of the present invention comprise administering 1 mg of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof to a patient twice daily to provide a total daily amount of 2 mg of sGC activator.

[0173] In another embodiment, the method of the present invention comprises administering to the patient 3 mg of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof.

[0174] In one embodiment, when used, the SGLT2 inhibitor is administered to the patient in a daily amount of 0.1 to 500 mg.

[0175] In another embodiment, when used, the SGLT2 inhibitor is empagliflozin.

[0176] In another embodiment, when used, empagliflozin is administered to the patient in a daily amount of 1, 2.5, 5, 10 or 25 mg.

[0177] In another embodiment, when used, empagliflozin is administered to the patient in a daily amount of 10 or 25 mg.

[0178] In another embodiment, when used, empagliflozin is administered to the patient in a daily amount of 10 mg.

[0179] In another embodiment, when used, empagliflozin is administered to a patient in an amount of 5 mg twice daily to provide a total daily amount of 10 mg of empagliflozin.

[0180] In another embodiment, the present invention relates to a method for treating a type 2 diabetic patient with CSPH in compensated cirrhosis due to NASH, the method comprising administering to the patient up to 3 mg (twice daily) of a sGC activator of the present invention or a pharmaceutically acceptable salt thereof in combination with empagliflozin.

[0181] In another embodiment, the present invention relates to the immediately above method, wherein the empagliflozin is administered in a daily amount of 10 mg; or in an amount of 5 mg administered twice a day.

[0182] Patients treated with the sCG activator of the present invention, or a combination of an sGC activator and an SGLT2 inhibitor, may be treated with one or more additional therapeutic agents. Non-limiting examples of such one or more additional therapeutic agents include compounds used to improve metabolic (e.g., obesity, diabetes, inflammation) conditions in patients. Non-limiting examples of such compounds include, for example, DPP-IV inhibitors (e.g., linagliptin, sitagliptin, saxagliptin, vildagliptin, and alogliptin), glitazones / thiazolidinediones (e.g., pioglitazone and rosiglitazone), glucagon-like peptide 1 (GLP-1)-based therapies (e.g., GLP-1 receptor agonists), metformin, insulin, and other metabolic disease antihypertensive drugs such as antihypertensive agents (e.g., diuretics, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARBs), adrenergic receptor antagonists, vasodilators, renin inhibitors, aldosterone receptor antagonists, and alpha-2 adrenergic receptor agonists) and statins (e.g., atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin).

[0183] For patients with NASH, treatment with the sGC activator of the present invention or a combination of the sGC activator and the SGLT2 inhibitor may further include treatment with compounds useful for treating NASH (including metabolic regulators, RAAS inhibitors, lipid regulators, antifibrotic agents, anti-inflammatory agents, and immunomodulators). Non-limiting examples of such NASH combination partners include:

[0184] PF-05221304 (Pfizer), obeticholic acid (Intercept), GS-0976 (Gilead), GS-9674 (Gilead), LJN452 (Novartis), LMB763 (Novartis), MSDC-0602K / Metabolic Solution (Octeca), EDP-305 (Enanta), INT-767 (Intercept), O304 (Betagenon), PF-06835919 (Pfizer), Semaglutide (Novo Nordisk), BMS-986036 (BMS), NGM282 (NGM), BMS-986171 (BMS), PF-06865571 (Pfizer), LIK066 (Novartis), ORMD 0801 (Oramed), CER-209 (Cerenis), TVB-2640 (3-V Bioscience), DS102 (Afimmune), MGL-3196 (Madrigal, Roche), VK2809 (Viking), Volixibat (Sanofi, Shire), IONIS-DGAT2Rx (Ionis), AKCEA-ANGPTL3-LRx (Akcea), Gemcabene (Gemphire), MT-3995 (Mitsubishi Tanabe), DUR-928 (Durect), CORT118335 (Corcept), amacizumab (BirdRock / Janssen), Elafibranor (Genfit), GRI-0621 (GRI Bio), Selonsertib (Gilead), Cenicriviroc (Takeda, Allergan), JKB121 (Taiwan), Saroglitazar (Zydus), IMM-124E (Immuron), Lanifibranor (IVA337) (Inventiva), GR-MD-02 (Galectin), Emricasan (VAY785) (Novartis), Tipelukast (Kyorin, MediciNova), BMS986263 (ND-L02-s201) ​​(BMS), PF-06667272 (Pfizer), Foralumab (Tiziana) and DRX-065 (DeuteRx).

[0185] In another embodiment, the NASH combination partner is selected from:

[0186] Acetyl-CoA carboxylase (ACC) inhibitors (e.g. GS-0976);

[0187] Amine oxidase copper-containing 3 (AOC3) inhibitors (e.g. BI 1467335 (formerly known as PXS-4728A));

[0188] Farnesoid X receptor (FXR) agonists (e.g., obeticholic acid);

[0189] Apoptosis signal-regulating kinase 1 (ASK1) inhibitors (e.g., sildenafil);

[0190] CC chemokine receptor type 2 (CCR2) and type 5 (CCR5) antagonists (e.g. ceniriviroc);

[0191] apoptotic protease inhibitors (e.g., enricasin);

[0192] peroxisome proliferator-activated receptor-gamma (PPAR) agonists (e.g., elafinol);

[0193] Stearoyl-CoA desaturase-1 inhibitors (such as aramchol);

[0194] Vascular adhesion protein-1 (VAP-1) inhibitors (e.g. PXS4728A); and

[0195] Pioglitazone / vitamins.

[0196]

Clinical trial plan

[0197] Clinical trials

[0198] The following describes a clinical trial protocol aimed at treating patients with CSPH with or without T2DM in compensated cirrhosis due to HBV, HCV, and NASH.

[0199] Trial objectives and endpoints

[0200] Primary Objective, Primary End Points, and Secondary End Points

[0201] Main Objectives

[0202] The trial will investigate the safety and tolerability of sGC activators in patients with CSPH with or without T2DM in compensated cirrhosis due to HBV, HCV, and NASH, and the combination of sGC activators and empagliflozin in patients with CSPH with T2DM in compensated cirrhosis due to NASH, who are on the highest standard of care, respectively. The primary objective is to estimate the percentage change from baseline in HVPG measured after 8 weeks. The primary analysis of baseline HVPG measurements will be performed for treated patients (Full Analysis Set, FAS), as if all patients were treated during the trial.

[0203] Primary End Point

[0204] The primary endpoint was the percent change from baseline in HVPG (measured in mmHg) after 8 weeks of treatment.

[0205] Secondary End Points

[0206] Secondary endpoints include:

[0207] - Response, defined as a >10% decrease in HVPG from baseline (measured in mmHg) after 8 weeks of treatment

[0208] - One or more decompensation events (i.e., ascites, VH, and / or overt HE) during the 8-week treatment period

[0209] - CTCAE Grade 3 (or higher) hypotension or syncope during the 8-week treatment period based on the investigator's judgment, with discontinuation of treatment due to hypotension or syncope during the 8-week treatment period.

[0210] Other goals and other end points

[0211] Other goals

[0212] In addition to the primary objective defined above, other objectives of the trial include evaluating general safety, PK, PD, biomarkers of disease activity, and further understanding of the use of non-invasive methods to study liver function and portal pressure.

[0213] Other endpoints

[0214] Other endpoints include, but are not limited to, those listed below.

[0215] - After 8 weeks of treatment Change from baseline in spleen stiffness (kPa) measured by Expert 630

[0216] - After 8 weeks of treatment Change from baseline in liver fat content (dB / m) measured by Expert 630CAP

[0217] - After 8 weeks of treatment Change from baseline in liver stiffness (kPa) measured by Expert 630LSM

[0218] - Change from baseline in metabolic function after 8 weeks of treatment, as measured by:

[0219] ○HbA1c

[0220] ○ Plasma glucose

[0221] ○HOMA-IR

[0222] - Change in body weight from baseline after 8 weeks of treatment

[0223] - Change from baseline in liver function after 8 weeks of treatment, as measured by:

[0224] ○PT / INR, aPTT

[0225] ○Bilirubin (direct and indirect)

[0226] ○ Liver enzymes (ALT, AST, γ-GT and alkaline phosphatase)

[0227] albumin

[0228] - Change from baseline in renal function, measured by eGFR, after 8 weeks of treatment

[0229] - Changes from baseline across disease-specific and mode-of-action exploratory biomarkers after 8 weeks of treatment and at EoS

[0230] ○Fibrosis markers (eg, PRO-C3, ELF score)

[0231] ○Inflammatory markers (e.g. hs-CRP)

[0232] ○ Cardiac and renal biomarkers (eg, brain natriuretic peptide (BNP), troponin I, eGFR, creatinine)

[0233] - If feasible, PK endpoints for sCG activators and empagliflozin will be determined:

[0234] ○C max(Maximum measured concentration of analyte in plasma)

[0235] ○t max (Time from dosing to maximum measured concentration of analyte in plasma)

[0236] ○AUC t1-t2 (Area under the concentration-time curve of the analyte in plasma at the time interval t1 to t2 after single dose administration)

[0237] ○C max,N (maximum measured concentration of analyte in plasma after N doses)

[0238] ○t max,N (Time from the last dose to the maximum measured concentration of the analyte in plasma after administration of N doses)

[0239] ○AUC t1-t2,N (Area under the concentration-time curve of the analyte in plasma at the time interval t1 to t2 after administration of the Nth dose)

[0240] ○C max,ss (maximum measured concentration of analyte in plasma at steady state within uniform dosing time interval τ)

[0241] ○t max,ss (The time from the last dose to the maximum measured concentration of the analyte in plasma at steady state within a uniform dosing interval τ)

[0242] ○AUC t1-t2,ss (Area under the concentration-time curve of the analyte in plasma at steady state within the time interval t1 to t2)

[0243] ○C pre,N (Pre-dose concentration of analyte in plasma immediately before administration of the Nth dose after administration of N-1 doses)

[0244] ○C pre,ss (Pre-dose concentration of analyte in plasma at steady state immediately before administration of the next dose)

[0245] ○C t,N (Concentration of analyte in plasma at time t after N doses)

[0246] o Other PK parameters may be calculated as appropriate.

[0247] The following additional endpoints will be measured based on data collected in countries where corresponding regulatory requirements are in place and implemented through country-specific local amendments to this protocol:

[0248] - Changes from baseline in liver function after 8 weeks of treatment using Dual bile salt clearance test, measured by the disease severity index (DSI) and related parameters

[0249] Additional endpoints may be defined in the trial statistical analysis plan (TSAP).

[0250] Description of Design and Trial Population

[0251] Overall Experimental Design

[0252] This phase II multinational, randomized, open-label, parallel-group trial investigated the effects of oral sGC activators alone and in combination with empagliflozin on portal hypertension after 8 weeks of treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis.

[0253] Once patients have signed informed consent, they will be enrolled in the trial and screened for eligibility. The screening period consists of up to 3 visits (Visits 1a, b, and c) and will last up to 4 weeks. Patients will be able to progress from one visit to the next when eligibility is confirmed at the previous visit. Evaluations will include gastroscopy, ultrasound of the liver and spleen, and HVPG measurements. Patients who remain eligible and successfully complete this period will continue into an 8-week open-label, active treatment period. A total of 80 patients will enter the trial, with 20 patients in the HBV arm (treatment arm 1), 20 patients in the HCV arm (treatment arm 2), and 40 patients in the NASH arm (treatment arms 3 and 4).

[0254] Both types of NASH patients (with or without a diagnosis of T2DM) will enter treatment group 3 or 4. NASH patients without a diagnosis of T2DM may enter treatment group 3 (sGC activator at high dose BID only) only at visit 2. NASH patients diagnosed with T2DM will be randomized in a 1:1 ratio to treatment group 3 (sGC activator at high dose BID only) or treatment group 4 (GC activator at high dose BID + empagliflozin QD) at visit 2. Once the number of patients in treatment group 3 reaches 20, recruitment of NASH patients without T2DM will be stopped and only patients with NASH with T2DM will be enrolled in treatment group 4 until the number of patients in this group reaches 20. Although randomization is applied, the investigators and trial sponsors will remain unblinded due to the open-label nature of this trial.

[0255] After enrollment and randomization at visit 2, patients will begin taking the trial drug and will enter the dose-titration period of the sGC activator. All patients in all 4 treatment groups will start taking a low dose BID of sGC activator during this period. If the low dose is tolerated, one week later (at visit 3, day 8), the dose of all patients will be titrated up to a medium dose BID of sGC activator. If this medium dose is tolerated, the second upward titration to a high dose BID of sGC activator will occur another week later (at visit 4, day 15). After the dose titration period, and if the dose is tolerated, the patient will maintain the highest dose of sGC activator for the remainder of the treatment period until it reaches the end-of-treatment (EoT) follow-up and 8 weeks of treatment. If the dose is not tolerated, the trial drug may be interrupted or the dose may be reduced / titrated down. In addition to the sGC activator, patients in treatment group 4 will begin receiving a fixed dose of empagliflozin QD at visit 2. Ultrasound of the liver and spleen will be repeated during the treatment period. and HVPG measurement (see Figure 1 ).

[0256] After the 8-week treatment period, all patients will enter a 4-week follow-up period without trial medication. A patient's participation in the trial will be complete when the patient has reached the last scheduled follow-up visit (i.e., end of study [EoS], 4 weeks after EoT).

[0257] Discussion of the experimental design (including the choice of control group)

[0258] A randomized, open-label, parallel-group design has been chosen for this exploratory trial, where the treatment period is very short and at the highest standard of care. The parallel groups will enable comparison of four different patient groups and the open-label design will provide benefits to all patients participating in the trial.

[0259] The 8-week treatment duration has been chosen to allow for the assessment of short-term efficacy and indirect comparison with the 8-week results of trial NCT05161481 (first published on December 17, 2021). The patient population of this trial (HBV, HCV, and NASH patients with and without T2DM) has been chosen because it represents a subset of the intended patient population for sGC activators (patients with clinically significant portal hypertension in compensated cirrhosis due to non-cholesterol liver disease).

[0260] In cohort 4, the combination of a sGC activator and empagliflozin will be investigated to evaluate the additional benefit of improved metabolism by a SGLT2 inhibitor (empagliflozin in this study) in patients with NASH and T2DM.

[0261] The measurement of HVPG was chosen as the primary endpoint because it is the gold standard for estimating portal pressure in patients with cirrhosis, i.e., assessing the severity of sinusoidal PH (see T. Reiberger et al., "Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)", Wien Klin Wochenschr 2017; 129(Suppl 3): S135-158)). It is used as an established surrogate marker for improvement and / or deterioration of liver fibrosis / function, because a decrease in HVPG translates into clinically meaningful benefits (see M. Mandorfer et al., "Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy", Hepatology 2020; 71(3); 1023-1036)).Several landmark studies have highlighted the prognostic value of HVPG, showing that HVPG ≥ 10 mmHg (i.e., CSPH) predicts the development of varicose veins (see RJ Groszmann et al., "Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis", N Engl J Med 2005; 353(21); 2254-2261), while (pharmacologically induced) reduction of HVPG modulates varicose growth and the corresponding risk of decompensation (see C. Merkel et al., "Gruppo Triveneto per l'Ipertensione Portale. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis", Gastroenterology 2004; 127(2); 476-484; and M. Mandorfer et al., "Hepatic venous pressure gradient response in cirrhosis", Journal of Clinical Oncology 2006 ... non-selective beta-blocker treatment—is it worth measuring? ” Curr Hepatol Rep 2019; 18; 174-186). Therefore, this also explains the choice of secondary endpoints related to the occurrence of one or more decompensation events.

[0262] Other secondary endpoints (development of significant hypotension or syncope and development of discontinuation due to hypotension or syncope) were selected because of their relevance based on the mechanism of action of sGC activators.

[0263] Patients will be screened for the trial based on eligibility criteria. These include selecting patients with documented endoscopically proven gastro-esophageal varices or documented endoscopically treated esophageal varices as preventive therapy, as varices only occur in patients with CSPH. At visit 1c (the final visit during the screening period), patients who remain eligible after visits 1a and 1b will undergo their first HVPG measurement. Those with HVPG ≥ 10 mmHg (based on local interpretation of pressure tracing) will continue to be eligible. With this approach, the trial is designed to recruit patients with CSPH, but the burden of invasive HVPG surgery will be reduced and only performed on patients who successfully reach visit 1c rather than on all screened patients.

[0264] Non-invasive evaluation (i.e., ultrasound and and functional liver tests) as part of the screening process to further investigate the patient's status, establish baseline values ​​for comparison with treatment, and further understand the use of noninvasive methods to investigate liver function and portal pressure. These assessments will be repeated (see Figure 1 ) to assess the time dependency of the treatment.

[0265] After enrollment / randomization, the trial design includes a dose titration period. The mechanism-related vasodilation of the sGC activator can lead to orthostatic dysregulation and hypotensive episodes. The orthostatic dysregulation is dose-limiting and clinical tolerability is improved if the dose is titrated. BID administration also allows the total daily exposure of the sGC activator to be further increased while avoiding high peak concentrations. Therefore, in this trial, a dose titration scheme of low dose BID to medium dose BID to high dose BID will be followed.

[0266] Selection of experimental groups

[0267] 80 patients with CSPH in compensated cirrhosis due to HBV, HCV and NASH with or without T2DM will be enrolled in this trial. Approximately 42 sites are planned in multiple countries. It is expected that 2 patients will be randomized at each site. Additional sites may be recruited if enrollment is delayed.

[0268] Screening of patients for this trial is competitive, i.e., once a sufficient number of patients have been screened to deliver the desired number of randomized patients, screening for this trial or one of the treatment arms will stop at all sites simultaneously. The investigator will be notified of the completion of screening and will then not be allowed to screen additional patients for this trial. Patients already in screening at this time will be allowed to continue randomization if eligible.

[0269] One retest during the Screening Period is permitted (e.g., if the Investigator believes that a failed laboratory test was the result of an error or extenuating circumstances, the test may be repeated once without rescreening the patient). This does not include endoscopy and HVPG measurement. One rescreening is also permitted, as long as the cause of the screening failure is reversible and resolved based on the Investigator's judgment. If a patient is initially ineligible for the trial and is subsequently rescreened, goes through a second informed consent process, receives a new unique patient number, and repeats the Screening Period assessment, the patient is considered a "rescreener."

[0270] Primary diagnosis at trial entry

[0271] The trial will include patients with compensated cirrhosis due to HBV, HCV, and NASH (with or without T2DM) with endoscopically documented gastroesophageal varices or endoscopically treated esophageal varices as preventive therapy, as a sign of CSPH, and HVPG ≥ 10 mmHg.

[0272] Inclusion criteria

[0273] - Signed and dated written informed consent in accordance with ICH-GCP and local regulations before admission to the trial

[0274] - Male or female ≥18 years of age (or legal age in countries where the legal age is greater than 18 years) and ≤75 years of age at screening (visit 1a)

[0275] - Clinical signs of CSPH as described in any of the following points. Each trial patient must undergo gastroscopy during the screening period (Follow-up 1b) or within 3 months before screening (Follow-up 1b).

[0276] ○ Documented endoscopic evidence of esophageal and / or gastric varices at screening (visit 1b) or within 3 months prior to screening (visit 1b)

[0277] ○ Documented endoscopic treatment of esophageal varices as preventive therapy

[0278] -CSPH, defined as baseline HVPG ≥10 mmHg (measured at visit 1c), based on local interpretation of pressure tracing

[0279] - A diagnosis of compensated cirrhosis due to HCV, HBV, or NASH with or without T2DM. The diagnosis of cirrhosis must be based on histology (historical data are acceptable) or clinical evidence of cirrhosis (e.g., platelet count <150 x 10 9 / L[150x 10 3 / μL], imaging-based nodular liver surface or splenomegaly, etc.)

[0280] ○ Diagnosis of NASH based on any of the following

[0281] Current or historical histologic diagnosis of NASH or steatosis

[0282] or

[0283] ■Clinical diagnosis of NASH based on historical or current imaging diagnosis of fatty liver ( At least 2 current or historical comorbidities of the metabolic syndrome (overweight / obesity, T2DM, hypertension, hyperlipidemia)

[0284] - Willing and able to undergo HVPG measurement per protocol (based on investigator judgment)

[0285] - If receiving a statin, must be on a stable dose for at least 3 months prior to screening (Visit 1b) with no planned dose changes throughout the trial

[0286] - If receiving NSBB or carvedilol, must be on a stable dose for at least 3 months prior to screening (Follow-up 1b) with no planned dose changes throughout the trial

[0287] - If receiving pioglitazone, GLP1-agonist, or vitamin E, must be on a stable dose for at least 3 months prior to screening (Visit 1b) with no planned dose changes throughout the trial

[0288] -WOCBP must be ready and able to use a highly effective birth control method in accordance with ICH M3(R2) that results in a low failure rate of less than 1% / year when used consistently and correctly from the randomization visit (Visit 2) until 7 days after the last treatment of the trial. The patient must agree to regular pregnancy testing during participation in the trial.

[0289] - Men who are of childbearing potential and have a CBP female sexual partner must use condoms with or without spermicide, or practice complete sexual abstinence, or have a vasectomy (with documentation of the absence of sperm in ejaculate as appropriate) from the randomization visit (Visit 2) until 7 days after the last treatment in the trial.

[0290] 3.3.3 Exclusion criteria

[0291] - Prior clinically significant decompensation events (e.g., ascites [not just perihepatic ascites], VH, and / or overt / apparent HE)

[0292] - History of other forms of chronic liver disease (eg, alcohol-related liver disease (ARLD), autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, haemachromatosis, alpha-1 antitrypsin [A1At] deficiency)

[0293] - Patients who are not receiving adequate treatment for HBV, HCV, or NASH as per local guidelines (eg, antiviral therapy for chronic HBV or HCV infection or lifestyle modification for NASH)

[0294] ○ If receiving curative antiviral therapy for HCV, no sustained virologic response (SVR) prior to screening or SVR lasting less than 2 years or if HCV RNA is detectable

[0295] ○ If receiving HBV antiviral therapy, was on a stable dose for less than 6 months prior to screening, had a planned dose change during the trial, and had detectable HBV DNA

[0296] ○ Weight change ≥ 5% in the 6 months prior to screening

[0297] - Must take or wish to continue taking any restrictive concomitant therapy or any concomitant therapy that is considered likely (based on the investigator's judgment) to interfere with the safe conduct of the trial

[0298] -SBP <100 mmHg and DBP <70 mmHg at screening (visit 1a)

[0299] - Model for End-Stage Liver Disease (MELD) score >15 at screening (visit 1a), calculated by central laboratory

[0300] - Hepatic impairment at screening (visit 1a), defined as Child-Turcotte-Pugh score ≥ B8, calculated by the site using central laboratory results

[0301] - ALT or AST >5 times upper limit of normal (ULN) at screening (visit 1a) as measured by central laboratory

[0302] -eGFR (CKD-EPI formula) <20 mL / min / 1.73 m at screening (visit 1a) 2 , measured by the central laboratory

[0303] -Alpha-fetoprotein >50 ng / mL (>50 microg / L) at screening (visit 1a) as measured by a central laboratory

[0304] - Active SARS-CoV-2 infection (or known positive test from screening [Visit 1a] until randomization [Visit 2])

[0305] - Previous orthotopic liver transplantation

[0306] - Previous or planned TIPS or other portal system bypass surgery

[0307] - Known portal vein thrombosis

[0308] - History of clinically relevant orthostatic hypotension, fainting spell, or blackout due to hypotension or of unknown origin (based on investigator's judgment)

[0309] - QTcF-interval >450ms in males or >470ms in females at screening (visit 1a), family history of long QT syndrome, or concomitant use of therapy with a known risk of Torsade de Pointes or plans to initiate such therapy during the trial

[0310] - History of type 1 diabetes or other autoimmune causes of diabetes (eg, LADA)

[0311] - Patients who, in the opinion of the investigator, are at increased risk for ketoacidosis.

[0312] - Any contraindications to the trial evaluation (e.g., poor patient cooperation during gastroscopy, pacemakers "if contraindicated, based on local market approval", etc.)

[0313] - Major surgery (based on the investigator's assessment), such as hip replacement, performed within 12 weeks before randomization (Visit 2) or planned during the trial.

[0314] - Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening (Follow-up 1a), except for appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix

[0315] - History of chronic substance abuse (within 6 months prior to randomization [Visit 2]) or ongoing chronic substance abuse, or anticipated noncompliance with protocol requirements for any other reason, which, in the investigator's judgment, makes the patient unreliable for trial recruitment or unlikely to complete the trial as scheduled

[0316] - Previous randomization in the trial, previous exposure to SCG activators, or allergy / contraindication to any of the sGC activators and / or excipients

[0317] - Currently enrolled in another investigational device or drug trial, or less than 30 days or 5 half-lives (whichever is longer) since completion of another investigational device or drug trial or receipt of other study treatment prior to randomization (Follow-up 2)

[0318] - Women who are pregnant, breastfeeding, or planning to become pregnant while on this trial

[0319] - Any other medical condition which, based on the investigator's judgment, poses a safety risk to the patient or may interfere with the objectives of the trial.

[0320] treat

[0321] The investigational drug products in this trial were sGC activators and empagliflozin.

[0322] Methods for assigning patients to treatment groups

[0323] After assessing all inclusion and exclusion criteria, each eligible patient will enter the treatment phase at Visit 2. HBV patients will be assigned to treatment group 1 and HCV patients to treatment group 2 via the interactive response technology (IRT) system. NASH patients with T2DM will be randomized 1:1 to treatment groups 3 or 4 via the IRT system. NASH patients without a diagnosis of T2DM will be assigned only to treatment group 3 via the IRT. Once the number of patients enrolled in treatment group 3 reaches 20, the IRT system will continue to recruit only NASH patients with T2DM to treatment group 4 until the total number of patients in that group also reaches 20.

[0324] Medication assignment and dosage for each patient

[0325] The trial medication will be allocated at the study site according to the flow chart. At the allocated visit, patients will be given the appropriate number of sGC activators (range 1 to 2) and empagliflozin (range 1 to 2) medication sets according to the time interval between visits. The last dose of sGC activator will be administered in the evening of the day before the EoT visit and the last dose of empagliflozin will be administered in the morning of the day before the EoT visit.

[0326] All patients will start at a low dose of sGC activator BID at Visit 2. In addition, treatment group 4 will receive a fixed dose of empagliflozin QD. All patients will be titrated up to a medium dose of sGC activator BID 7 days later at Visit 3 and 7 days after Visit 3, again at Visit 4, and then to a high maintenance dose of sGC activator BID.

[0327] Patients will be informed of the dose titration period and will be aware of the up-titration of sGC activators being used. Starting from Visit 4, patients in Treatment Groups 1, 2, 3, and 4 will continue to receive the maximum dose of high-dose sGC activator (plus empagliflozin QD for Group 4 only) until the EoT visit is reached (8 weeks after starting trial drug).

[0328] From the start of the treatment period (i.e., from visit 2) and until the EoT visit is reached 8 weeks later, patients will be instructed to take the sGC activator orally twice a day (BID) and empagliflozin orally once a day (QD). Each dose of sGC activator will consist of one film-coated tablet. It is recommended to take the first daily dose in the morning and the second dose in the evening. Ideally, there should be at least 10 hours between the intake of each dose. The sGC activator should be taken at about the same time every day. If a dose is missed, it should not be corrected by taking two doses (i.e., double doses) at the next time point; if a dose is missed for more than 6 hours, the dose should be skipped entirely and the next dose taken as scheduled. The trial drug should be taken with a glass of water and may be taken with or without food.

[0329] Patients in treatment group 4 will take an additional film-coated tablet of empagliflozin in the morning along with the first daily dose of sGC activator. To ensure an approximately 24-hour dosing interval for empagliflozin, the drug should be taken at approximately the same time each morning. If a dose of empagliflozin is missed by more than 12 hours, the dose should be skipped and the next dose should be taken as scheduled. Double doses should not be taken. Both drugs should be taken with a glass of water and may be taken with or without food.

[0330] limit

[0331] Restrictions on concomitant therapy

[0332] The following concomitant therapies should not be administered to patients diagnosed with NASH. These restrictions apply for 5 half-lives from the cessation of concomitant therapy prior to enrollment (Visit 2) until the EoS visit.

[0333] - Other SGLT2 or SGLT-1 / 2 inhibitors

[0334] Concomitant therapies mentioned below must not be co-administered with sGC activators.

[0335] - NO-sGC-cGMP pathway activating therapies such as NO-donors (e.g. glyceryl trinitrate, isosorbide di- or mononitrate, molsidomine), PDE-5-inhibitors (e.g. sildenafil, tadalafil and vardenafil), non-specific PDE inhibitors such as dipyridamole and theophylline, or sGC-stimulators (e.g. riociguat): These restrictions apply within 5 half-lives since cessation of concomitant therapy before inclusion (visit 2) until the EoS visit.

[0336] - Concomitant therapy with known risk of Torsade de Pointes: These restrictions apply from Screening Visit 1a until EoS Visit. If this therapy is used temporarily, the trial drug must be temporarily discontinued and may then be restarted at least 5 half-lives after the concomitant therapy with known risk of Torsade de Pointes has been discontinued.

[0337] The following concomitant therapies and co-administration of any trial drug (sGC activator and empagliflozin) were not permitted within 5 half-lives after cessation of concomitant therapy prior to enrollment (Visit 2) until the EoS visit.

[0338] - Clinically relevant OATP1B1 / 3 inhibitors

[0339] - Clinically relevant concomitant therapy known to inhibit or induce UGT enzymes

[0340] In case of temporary concomitant use of an unapproved drug, the sGC activator and / or empagliflozin must be temporarily discontinued and may be restarted after a period of at least 5 half-lives after the concomitant therapy has been discontinued. If permanent use of any of the above prohibited therapies is required, both investigational drugs should be discontinued.

[0341] In addition, patients receiving statins, or NSBBs / carvedilol, pioglitazone, GLP1-agonists, or vitamin E must be on a stable dose for at least 3 months prior to screening (visit 1b) with no planned dose changes throughout the trial. Furthermore, such concomitant therapies should not be initiated during the trial as they could interfere with the efficacy of the trial drug.

[0342] If receiving antiviral therapy for HBV, patients had to be on a stable dose for at least 6 months prior to screening with no planned dose changes throughout the trial.

[0343] Close monitoring of AEs based on concomitant therapy

[0344] Close monitoring for AEs is recommended in this trial if patients are taking concomitant therapies that are metabolized by CYP3A4, have a narrow therapeutic index, and / or are sensitive substrates.

[0345] Evaluate

[0346] Evaluation of efficacy

[0347] Hepatic venous pressure gradient

[0348] The HVPG procedure within the trial will be implemented in a standardized manner across all sites; training will be provided. If not already provided for trial 1366-0021, each trial site will be required to provide an acceptable sample HVPG trace prior to commencing patient recruitment. Measurements of wedge hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be performed in triplicate; traces will be provided to external vendors and read centrally by an independent PH expert; the central reading will include a subjective assessment of the overall trace quality as well as the associated pressure readings. The independent expert will be blinded to the time points associated with the trace. The central reading will include traces from visit 1c, which have also been interpreted locally. The results of the central reading will be transferred to the trial sponsor and will be considered the official evaluation of the trial. In the event of a discrepancy between the local interpretation and the central evaluation (e.g., visit 1c trace), the central evaluation will remain valid.

[0349] The HVPG measurement should be performed before ingestion of the study drug, after an overnight fast, and ideally in the morning using the same hepatic vein. If it is not possible to perform the measurement in the morning at visit 1c, an alternative time of day may be chosen; in this case, a fast of at least four hours is required. All subsequent HVPG measurements must then be performed for a single patient at approximately the same time of day as the measurement at visit 1c. If visits 1b and 1c are performed on the same day, the HVPG measurement must be performed after the gastroscopy (i.e. only after confirmation that the patient is still eligible for the trial). During the treatment period, after randomization, the HVPG measurement should be performed on the day of the scheduled visit or within seven days (if the latter approach is adopted, the measurement should still be performed after an overnight fast / after a fast of at least four hours).

[0350] An overview of the HVPG procedure is as follows (see T. Reiberger et al., "Measurement of the hepaticvenous pressure gradient and transjugular liver biopsy", J Vis Exp 2020(160); e58819).

[0351] Under local anesthesia and ultrasound guidance, the catheter guide sheath is placed in the right internal jugular vein. Using fluoroscopic guidance, the balloon catheter is advanced into the inferior vena cava (IVC) and inserted into the large hepatic vein. The correct and sufficient wedge position of the catheter is ensured by injecting contrast media while the balloon blocks the outflow of the cannulated hepatic vein. After calibrating the external pressure transducer, the triplicate recordings of WHVP and FHVP are utilized to obtain continuous pressure recordings. The difference between FHVP and WHVP is called HVPG, and its value ≥10mmHg indicates CSPH. Before removing the catheter, the pressure readings and right atrial pressure obtained at the same level in the IVC are recorded.

[0352] Measurement

[0353] Will use Expert 630 device (a device using vibration controlled transient elastic imaging (VCTE) TM ) technology to evaluate the liver and spleen. It has been available for many years and is standard procedure for screening and managing patients with liver disease. Expert 630 model and later, use The ability to assess spleen stiffness is only just becoming available; therefore, spleen stiffness measurement is not yet a standard part of clinical practice in the patient population planned for this trial.

[0354] The assessment will be done after an overnight stay. This can be done at Visit 1b or 1c. During the treatment period, following randomization, the assessment should be done on the day of the scheduled visit, or within seven days (if the latter approach is used, the measurement must still be done after an overnight fast).

[0355] The following assessments will be conducted:

[0356] -Using VCTE TM Liver Stiffness Measurement (LSM)

[0357] - Liver fat using controlled attenuation parameters (CAP)

[0358] -Using VCTE TM Measurement of spleen stiffness.

Claims

1. A method for treating a patient with compensated cirrhosis, the method comprising administering to the patient a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator of formula (I), in: A is a 5- to 7-membered saturated heterocyclic group containing one nitrogen and optionally one oxygen, wherein one carbon of the heterocyclic group is optionally substituted by one or two carbon atoms selected from C 1-3 Alkyl and oxo group substitution; R 1 is C optionally substituted by methoxy 1-4 alkyl; R 2 Selected from H, F, Cl, C 1-3 Alkyl, -CN, -OMe and -CF3; R 3 Selected from H and -CH3; R 4 is selected from H, F, -CH3 and -OMe; R 5 is selected from H, Cl, -CH3, -CH2CH3, -CF3, F and -OMe; R 6 bonded to the nitrogen on A and selected from H, C 1-6 Alkyl, -(CH2) n C 3-6 Cycloalkyl, -C(O)C 1-6 Alkyl, -(CH2) n Heterocyclic group, -(CH2) n Aryl, -(CH2) n Heteroaryl, -SO2aryl, SO2C 1-6 Alkyl, wherein the C 1-6 Alkyl, -(CH2) n Heterocyclic group, -(CH2) n Cycloalkyl, -(CH2) n Aryl and -(CH2) n Heteroaryl is optionally substituted by one to four independently selected 1-3 Alkyl, halogen, C 1-3 Alkoxy, -CF3, -OH, oxo, -(CH2) 1-3 O(CH2) 2-3 OH and -SO2CH3 group substitution; R 7 is selected from H, -CH3, -CH2CH3, -CF3, F and -CN; n is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the patient has clinically significant portal hypertension in compensated cirrhosis.

3. The method of claim 2, wherein the compensated cirrhosis is due to or caused by hepatitis B virus (HBV), hepatitis C virus (HCV) or non-alcoholic steatohepatitis (NASH).

4. The method of claim 3, wherein the compensated cirrhosis is due to or caused by HBV.

5. The method of claim 3, wherein the compensated cirrhosis is due to or caused by HCV.

6. The method of claim 3, wherein the compensated cirrhosis is due to or caused by NASH.

7. The method of claim 6, wherein the patient suffers from type 2 diabetes.

8. The method according to any one of claims 1 to 7, further comprising administering to the patient a pharmaceutically effective amount of a SGLT2 inhibitor or a pharmaceutically acceptable salt thereof.

9. The method according to claim 8, wherein the SGLT2 inhibitor is selected from the group consisting of empagliflozin, dapagliflozin and canagliflozin.

10. The method according to claim 9, wherein the SGLT2 inhibitor is empagliflozin.

11. The method according to any one of claims 8 to 10, wherein the SGLT2 inhibitor is administered to the patient twice daily.

12. The method according to any one of claims 8 to 10, wherein the SGLT2 inhibitor is administered to the patient once daily.

13. A compound for use in treating a patient with compensated cirrhosis, wherein the compound has formula (I), in: A is a 5- to 7-membered saturated heterocyclic group containing one nitrogen and optionally one oxygen, wherein one carbon of the heterocyclic group is optionally substituted by one or two carbon atoms selected from C 1-3 Alkyl and oxo group substitution; R 1 is C optionally substituted by methoxy 1-4 alkyl; R 2 Selected from H, F, Cl, C 1-3 Alkyl, -CN, -OMe and -CF3; R 3 Selected from H and -CH3; R 4 is selected from H, F, -CH3 and -OMe; R 5 is selected from H, Cl, -CH3, -CH2CH3, -CF3, F and -OMe; R 6 bonded to the nitrogen on A and selected from H, C 1-6 Alkyl, -(CH2) n C 3-6 Cycloalkyl, -C(O)C 1-6 Alkyl, -(CH2) n Heterocyclic group, -(CH2) n Aryl, -(CH2) n Heteroaryl, -SO2aryl, SO2C 1-6 Alkyl, wherein the C 1-6 Alkyl, -(CH2) n Heterocyclic group, -(CH2) n Cycloalkyl, -(CH2) n Aryl and -(CH2) n Heteroaryl is optionally substituted by one to four independently selected 1-3 Alkyl, halogen, C 1-3 Alkoxy, -CF3, -OH, oxo, -(CH2) 1-3 O(CH2) 2-3 OH and -SO2CH3 group substitution; R 7 is selected from H, -CH3, -CH2CH3, -CF3, F and -CN; n is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.

14. A compound according to claim 13 for use in the treatment of patients with clinically significant portal hypertension in compensated cirrhosis.

15. A compound according to claim 13 for use in the treatment of patients with clinically significant portal hypertension in compensated cirrhosis due to or caused by hepatitis B virus, hepatitis C virus or non-alcoholic steatohepatitis.

16. A compound according to claim 13 for use in the treatment of patients with clinically significant portal hypertension in compensated cirrhosis of the liver, wherein the compensated cirrhosis is due to or caused by the Hepatitis B virus.

17. A compound according to claim 13 for use in the treatment of patients with clinically significant portal hypertension in compensated cirrhosis due to or caused by the Hepatitis C virus.

18. A compound according to claim 13 for use in the treatment of patients with clinically significant portal hypertension in compensated cirrhosis due to or caused by non-alcoholic steatohepatitis.

19. A compound according to claim 13 for use in the treatment of type 2 diabetic patients with clinically significant portal hypertension in compensated cirrhosis due to or caused by non-alcoholic steatohepatitis.

20. The compound according to claim 13 and the use according to any one of claims 12 to 18, wherein the compound according to claim 13 is administered to the patient twice a day.

21. The compound according to claim 13 and the use according to any one of claims 13 to 20, wherein the patient is further treated with a SGLT2 inhibitor.

22. The use according to claim 21, wherein the SGLT2 inhibitor is selected from the group consisting of empagliflozin, dapagliflozin and canagliflozin.

23. The use according to claim 22, wherein the SGLT2 inhibitor is empagliflozin.

24. Use according to any one of claims 21 to 23, wherein the SGLT2 inhibitor is administered to the patient twice a day.

25. The use according to any one of claims 21 to 23, wherein the SGLT2 inhibitor is administered to the patient once a day.

26. The method according to any one of claims 1 to 12 or the use according to any one of claims 13 to 25, wherein the compound of formula (I) is selected from the group consisting of any one of the compounds described in Table 1 and pharmaceutically acceptable salts thereof.

27. The method according to any one of claims 1 to 12 or the use according to any one of claims 13 to 25, wherein the compound of formula (I) is selected from the group consisting of compound numbers 18, 27, 84, 114, 133, 134, 136, 148, 154, 165 and 167: and pharmaceutically acceptable salts thereof.

Citation Information

Patent Citations

  • Alkoxy pyrazoles as soluble guanylate cyclase activators

    WO2014039434A1

  • Alkoxy pyrazoles as soluble guanylate cyclase activators

    WO2020011804A1